Neuronetics Q1 revenue $34.5M (+8% YoY); net loss improves; maintains FY2026 outlook

Neuronetics, Inc.

2026-Q1 EPS reported -$0.16 revenue$34,454,000

Revenue $34.5M (+8% YoY); U.S. clinic revenue $21.5M (+15%) on Greenbrook acquisition and SPRAVATO expansion.
Net loss $(10.8M) ($0.16/shr) vs $(12.7M) loss a year ago; operating expenses down 6% to $25.1M.
Cash $19.0M (incl. $5.8M restricted); made $5M debt principal payment in March to reduce debt.
Optum/UHC/UBH expanded TMS policy to allow nurse practitioners to order/administer NeuroStar, covering 34.8M lives across 26 states.
FY2026 guidance: revenue $160-166M, gross margin 47-49%, op ex $100-105M, cash from ops negative $13-17M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Neuronetics, Inc. reported three months ended March 31, 2026 results: revenue $34.5 million, net income $(10.8) million, EPS $(0.16) per share. Guidance reaffirmed.

Period: three months ended March 31, 2026
Revenue: $34.5 million
Net income: $(10.8) million
EPS: $(0.16) per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the three months ended March 31, 2026 was $34.5 million, an increase of $2.5 million, or 8%, compared to the three months ended March 31, 2025 revenue of $32.0 million.

View on SEC.gov

Browse all earnings releases →

Neuronetics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-205117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.